Free Trial
→ You’re Being LIED To About The Iran War (From Banyan Hill Publishing) (Ad)tc pixel
NASDAQ:GHRS

GH Research Q2 2025 Earnings Report

GH Research logo
$21.28 -0.41 (-1.89%)
Closing price 04:00 PM Eastern
Extended Trading
$21.09 -0.19 (-0.89%)
As of 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
ProfileEarnings HistoryForecast

GH Research EPS Results

Actual EPS
-$0.15
Consensus EPS
-$0.22
Beat/Miss
Beat by +$0.07
One Year Ago EPS
N/A

GH Research Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

GH Research Announcement Details

Quarter
Q2 2025
Date
8/7/2025
Time
Before Market Opens
Conference Call Date
Wednesday, August 6, 2025
Conference Call Time
6:00PM ET

Upcoming Earnings

GH Research's Q1 2026 earnings is estimated for Thursday, May 7, 2026, based on past reporting schedules

Conference Call Resources

Powered by Quartr

Earnings Documents

GH Research's Q2 2025 Earnings ReleaseEarnings Release
(8-K)

GH Research Earnings Headlines

GH Research Raises $111 Million in Completed Share Offering to Fund Depression Pipeline
April 30, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/gh-research-raises-111-million-in-completed-share-offering-to-fund-depression-pipeline?utm_source=marketbeat.com&utm_medium=referral
GH Research Announces Pricing of $117.5 Million Underwritten Offering
April 29, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/04/29/3283701/0/en/gh-research-announces-pricing-of-117-5-million-underwritten-offering.html
Iran's New Leader Just Said Something That Should Terrify Every American
Iran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of the world's oil passing through that corridor, crude has already crossed $100 per barrel. History shows gold surged 571% during the 1973 oil crisis and 425% in 1979. Today, the U.S. holds 8,133 tonnes of gold valued on the books at $42.22 per ounce - while gold trades above $5,000. American Alternative Assets has released The Great Gold Reset report detailing what this gap could mean for investors.tc pixel
May 5 at 1:00 AM  |  American Alternative (Ad)
GH Research: WH Decision On Psychedelics To Treat Depression Makes Bull Case
April 20, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4892025-gh-research-wh-decision-on-psychedelics-to-treat-depression-makes-bull-case
GH Research Welcomes White House Executive Order to Accelerate Medical Treatments for Serious Mental Illness
April 20, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/04/20/3277100/0/en/gh-research-welcomes-white-house-executive-order-to-accelerate-medical-treatments-for-serious-mental-illness.html
Here's Why We're Not At All Concerned With GH Research's (NASDAQ:GHRS) Cash Burn Situation
April 4, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/markets/stocks/articles/heres-why-were-not-concerned-140601844.html
See More GH Research Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like GH Research? Sign up for Earnings360's daily newsletter to receive timely earnings updates on GH Research and other key companies, straight to your email.

About GH Research

GH Research (NASDAQ:GHRS) Holdings Inc is a clinical-stage biotechnology company dedicated to the development of novel treatments for neuropsychiatric disorders through the application of psychedelic-inspired compounds. Headquartered in Dublin, Ireland, the company focuses on harnessing the unique pharmacology of 5-methoxy-N-dimethyltryptamine (5-MeO-DMT) and related molecules to address high unmet medical needs in mental health.

The firm’s lead program, GH001, is an inhaled formulation of 5-MeO-DMT that has completed early-stage clinical trials assessing safety, tolerability and preliminary efficacy in treatment-resistant depression. An additional preclinical candidate, GH002, is being developed for broader indications including anxiety, cognitive impairment and substance use disorders. GH Research employs a proprietary platform to optimize dosing, formulation delivery and real-time patient monitoring.

Founded in 2017 by biotechnology entrepreneur Christian Angermayer, GH Research operates research facilities in Ireland and maintains collaborations with academic institutions and contract research organizations across Europe and North America. The executive leadership team combines expertise in psychiatry, neuroscience and drug development to advance the company’s pipeline.

GH Research engages with regulatory authorities in multiple jurisdictions as it plans to initiate later-stage clinical trials and pursue strategic partnerships. The company’s goal is to bring innovative, psychedelic-derived therapeutics to patients worldwide who face debilitating psychiatric conditions.

View GH Research Profile
Earnings Tools